In addition, we also assess the biological basis of mutual exclusivity of biallelic ATM and TP53 alterations in CLL, underscoring the importance of the number of alleles affected by these alterations in CLL, establishing novel pre‐clinical models for the study of the biology and therapeutic response of concurrent genetic abnormalities in the disease. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.